<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study, we have investigated the clinical effectiveness of <z:chebi fb="2" ids="46081">fluconazole</z:chebi> (FLCZ) given intravenously or orally to pediatric patients with <z:e sem="disease" ids="C0553576" disease_type="Disease or Syndrome" abbrv="">systemic fungal infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>FLCZ was administered intravenously to two patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (multiple <z:e sem="disease" ids="C0948689" disease_type="Disease or Syndrome" abbrv="">hepatosplenic candidiasis</z:e> and <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e>) and orally to two <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">mycosis</z:e> complicated with <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical efficacies were excellent and no side effects were observed in any patients </plain></SENT>
<SENT sid="3" pm="."><plain>Pharmacokinetic analysis in 6 neonates revealed that the plasma half-life is 37-41 hours after administration of single dose of intravenous infusion of 3 mg/kg of FLCZ </plain></SENT>
</text></document>